United Therapeutics
UTHR
406 hedge funds and large institutions have $6.81B invested in United Therapeutics in 2016 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 126 increasing their positions, 165 reducing their positions, and 42 closing their positions.
112% more ownership
Funds ownership: 0% → 112% (+112%)
45% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 42
19% more capital invested
Capital invested by funds: $5.72B → $6.81B (+$1.09B)
3% more funds holding
Funds holding: 394 → 406 (+12)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
16% less call options, than puts
Call options by funds: $35.5M | Put options by funds: $42.5M
24% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 165
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$50.6M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$29.4M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$29.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$19.6M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$108M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$30.4M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$28.7M |
| 4 |
Millennium Management
New York
|
-$25.2M |
| 5 |
Citigroup
New York
|
-$25.1M |
UTHR Hedge Fund Activity: Q4 2016 in Review
406 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2016, worth a combined $6.81B — up 19% from $5.72B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new UTHR positions and 42 closed out — a net gain of 19 holders — while 126 added to existing stakes and 165 trimmed.
The largest buyer was Wells Fargo, adding an estimated $50.6M. The largest seller was Scopia Capital Management, cutting an estimated $108M.
- 406 institutional investors held United Therapeutics (UTHR) as of Q4 2016, up from 394 in Q3 2016.
- Funds reported $6.81B of United Therapeutics stock for Q4 2016, up 19% quarter-over-quarter.
- 61 funds opened new United Therapeutics positions in Q4 2016 and 42 closed out, a net change of +19 holders.
- The largest United Therapeutics buyer in Q4 2016 was Wells Fargo, an estimated $50.6M added.
- The largest United Therapeutics seller in Q4 2016 was Scopia Capital Management, an estimated $108M sold.
Based on aggregated 13F filings for Q4 2016.